ST
INSY

Smithfield Trust’s Insys Therapeutics, Inc. INSY Stock Holding History

Smithfield Trust’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-188
Closed -$2K – 854
2016
Q3 		$2K Hold
188
– – ﹤0.01% 798
2016
Q2 		$2K Hold
188
– – ﹤0.01% 789
2016
Q1 		$3K Hold
188
– – ﹤0.01% 785
2015
Q4 		$5K Hold
188
– – ﹤0.01% 777
2015
Q3 		$5K Hold
188
– – ﹤0.01% 737
2015
Q2 		$7K Hold
188
– – ﹤0.01% 736
2015
Q1 		$5K Buy
+188
New +$4.97K ﹤0.01% 745

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Smithfield Trust's INSY Position: Q4 2016 in Review

Smithfield Trust sold out of Insys Therapeutics, Inc. (INSY) in Q4 2016, closing a stake of 188 shares — an estimated $2K sold.

Smithfield Trust first reported a position in INSY in Q1 2015 and held it in 7 quarters. The position peaked at $7K in Q2 2015. 138 funds tracked by Wall St. Rank hold INSY as of Q4 2016.

  • Smithfield Trust reported no remaining Insys Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Smithfield Trust sold 188 Insys Therapeutics, Inc. shares in Q4 2016, an estimated $2K.
  • Smithfield Trust first reported a position in Insys Therapeutics, Inc. in Q1 2015 and held it in 7 quarters.
  • Smithfield Trust's Insys Therapeutics, Inc. position peaked at $7K in Q2 2015.
  • 138 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2016.

Based on Smithfield Trust's 13F filing for Q4 2016, filed 8 Feb 2017.